A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Kamyar Kalantar-Zadeh, MD UC Irvine School of Medicine Irvine, CA, USA
Kalantar shares data that suggest that epigenetic modification with the BET inhibitor apabetalone may improve factors involved in the pathogenesis of CKD, including alkaline phosphatase.
Video navigation menu
- Patients with diabetes and CKD have strongly elevated CV risk - can epigenetic therapy address this unmet need? 0:44
- How may the BET protein inhibitor apabetalone affect gene expression and disease? 2:21
- Experimental evidence suggests that apabetalone can attenuate calcification and alkaline phosphatase levels 5:42
- Can apabetalone modify alkaline phosphatase levels and CKD? First trial results of apabetalone therapy 12:56
- Recent evidence on the impact of apabetalone on renal disease 17:05
- Hypothetical model of how selective BET inhibition lowers alkaline phosphatase, to improve CKD and CVD outcomes 22:16
This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.
Kamyar Kalantar-Zadeh, MD, MPH, PhD, is a specialist in Nephrology and Professor of Medicine and Public Health at UC Irvine School of Medicine.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.